The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Fitness technology MyFiziq has signed Evolt360. MyFiziq technology is intended to extend the Evolt reach to the hands of consumers at home.

Evolt is a machine based body scanning technology which is supported by health, fitness and wellness companies such as F45, Anytime Fitness, and Life Fitness Distributors.

These companies are looking to provide greater insight into the health of its members and employees.

A low-intensity electrical current is passed through the body, via the feet and hands, and it determines the difference between muscle mass, fat mass, minerals, and water.

The machines cost between $12,000-$20,000 with trained staff to run them and the scans cost between $30-$50 per person depending on the type of scan performed.

MyFiziq uses images from phone to create a realistic 3D avatar of your body which allows for customers to track changes and even buy clothing online.

Co-Founder and Chief Executive Officer of Evolt is excited to show what the future could hold.

“I am extremely confident this is the future of digital dimension, having the ability to place in in the palm of the consumer’s hand and is highly complementary to our offering and strategic decision,” he said.

There are currently more than 4,000 new orders which will begin rolling out soon.

Please find announcement attached here: https://hotcopper.com.au/data/pricesensitive/announcements/ASX/6A926641_MYQ.html

MYQ by the numbers
More From The Market Online

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…

Genetic Signatures wins TGA greenlight for flu test device – just before winter

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported…

PYC Therapeutics takes Polycystic Kidney Disease drug to human trials

PYC Therapeutics takes its latest drug for Polycystic Kidney Disease, characterized by the formation of cysts…